Concurrent radiation therapy and irinotecan in stage IIIB cervical cancer.
Artículo
en Inglés
| IMSEAR
| ID: sea-45654
ABSTRACT
The present study was to evaluate the efficacy and toxicity of concurrent radiation therapy and irinotecan in patients with stage IIIB cervical cancer. Fifteen patients with no prior radiation therapy and chemotherapy were enrolled in the study. These patients received 50 Gy of external radiation to whole the pelvis, 50 Gy with an additional dose of 6-10 Gy to the parametrium and 1 or 2 sessions of intracavitary Cesium-137. Weekly intravenous infusion of 40 mg/m2 irinotecan was given for 5 cycles during the course of radiation therapy. Of 14 evaluable patients, 4 (28.6%) achieved complete response and 7 (50.0%) achieved partial response. Treatment-related toxicity included grade 1 & 2 anemia, grade 1 & 2 leucopenia, grade 1 & 2 neutropenia and 7.1 per cent grade 3 diarrhea. No grade 4 toxicity or treatment-related death occurred in the present study. CONCLUSION:
Irinotecan is a promising new cytotoxic agent in treatment concurrently with radiation therapy in newly diagnosed locally advanced cervical cancer. This modality of treatment appeared to be effective with acceptable toxicity.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Dosis de Radiación
/
Fármacos Sensibilizantes a Radiaciones
/
Tailandia
/
Femenino
/
Humanos
/
Camptotecina
/
Carcinoma de Células Escamosas
/
Neoplasias del Cuello Uterino
/
Estudios de Seguimiento
/
Resultado del Tratamiento
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
País/Región como asunto:
Asia
Idioma:
Inglés
Año:
2003
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS